- PR Newswire•20 days ago
LOS ANGELES, Sept. 6, 2016 /PRNewswire/ -- SNN Incorporated, a global multimedia financial news and publishing company focused on the MicroCap stock market, and publisher of the MicroCap Review Magazine, ...
- Accesswire•last monthWallStreet Research(TM) Announces Availability of Updated Corporate Profile Coverage on Pressure BioSciences, Inc. (OTCQB: PBIO)
NEW YORK, NY / ACCESSWIRE / August 18, 2016 / WallStreet Research™, a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated corporate ...
- Zacks Small Cap Research•last month
Total revenue for 2Q16 was $0.51 million, as compared to $0.41 million during the three months ended June, 2015, an increase of 24%. Two major drivers of product revenue growth were instrument sales, which increased 43% during the comparative quarterly periods (from $217,138 to $311,345) and consumable sales, which increased 29% (from $56,513 to a record $72,773). This decrease in grant revenue, which is expected to be short-term, allowed the Company to focus grant personnel in other critical areas during the second quarter of 2016, primarily in the development of the Barocycler 2320EXTREME, the company’s next-generation instrument system, and in various sales & marketing activities. The additional efforts in sales/marketing were partially responsible for the 24% increase reported in quarterly total revenue, from $413,104 in Q2 2015 to $510,963 in Q2 2016, despite the short-term decrease in grant revenue.
Pressure BioSciences, Inc. (PBIO)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.30 - 0.34|
|52wk Range||0.20 - 0.58|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.75|
|Avg Vol (3m)||44,203|
|Dividend & Yield||N/A (N/A)|